Amicus Therapeutics Discloses Preliminary 2025 Financials Ahead of BioMarin Acquisition
Summary
Amicus Therapeutics released preliminary unaudited financial results for 2025, reporting approximately $634 million in total net product revenues and $294 million in cash, cash equivalents, and marketable securities, provided in connection with the pending acquisition by BioMarin Pharmaceutical Inc.
Key Events
-
Preliminary 2025 Financials Disclosed
Amicus Therapeutics provided preliminary unaudited financial information for the year ended December 31, 2025, in connection with its proposed acquisition by BioMarin Pharmaceutical Inc.
-
Strong Revenue Performance
The company estimates total net product revenues of approximately $634 million for 2025, including $522 million from Galafold® and $112 million from Pombiliti® + Opfolda®.
-
Solid Cash Position
As of December 31, 2025, Amicus estimates it had approximately $294 million in cash, cash equivalents, and marketable securities.
-
Supports Acquisition Financing
These financial estimates were provided to BioMarin Pharmaceutical Inc. for inclusion in its preliminary offering memorandum related to a proposed private placement of senior notes to fund the acquisition.
Analysis
This 8-K provides preliminary, unaudited financial results for the full year 2025, including strong product revenues and a solid cash position. These figures were provided to BioMarin Pharmaceutical Inc. to support its proposed private placement of senior notes, which will fund the previously announced acquisition of Amicus Therapeutics. The disclosure offers investors a timely look at the company's performance leading into the merger, reinforcing the financial health of the target company. While these are estimates and subject to change, they offer positive context for the ongoing acquisition process.
At the time of this filing, FOLD was trading at $14.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $5.51 to $14.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.